According to the new market research report “Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) – Global Forecast to 2023“, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
The global superdisintegrants market is projected to reach USD 536.5 million by 2023 from USD 366.4 billion in 2018, at a CAGR of 7.9%. Factors contributing to the growth of this market include the increasing adoption of orally disintegrating tablets, growing generics market, and the emergence of new superdisintegrants for the pharmaceutical industry. The shifting focus of pharmaceutical manufacturing to emerging markets and the growth of the overall pharmaceutical sector in these markets present significant opportunities for the superdisintegrants market growth.
The report analyzes the global superdisintegrants market by type, formulation, therapeutic area, and region. By type, the synthetic superdisintegrants segment accounted for the largest share of the market in 2017. The large share of this segment can be attributed to the extensive consumption of these superdisintegrants in various pharmaceutical drug formulations due to the advantages offered such as effectiveness at lower concentrations as compared to starch and a lesser effect on the compressibility and flowability of the dosage form.
Browse and in-depth TOC on “Superdisintegrants Market ”
124 – Tables
37 – Figures
182 – Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/superdisintegrants-market-198068672.html
Based on formulation, the tablets segment accounted for the larger share of the global superdisintegrants market in 2017. The large share of this segment can be attributed to tablets being the most widely used dosage forms due to the benefits offered such as stability, low manufacturing cost (as compared to other dosage forms), easy product identification, and compactness, along with the increasing focus on orally disintegrating tablets and fast-dissolving tablets.
Based on therapeutic area, the neurological diseases segment is expected to register the highest CAGR during the forecast period. This can be attributed to the increasing incidences of neurological disorders at the global level along with the growing demand for effective therapies.
Discount Available on Report @ https://www.marketsandmarkets.com/discountreports.asp?id=198068672
During this research study, major players operating in the superdisintegrants market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.
Major Players:
Key players considered in the analysis of the superdisintegrants market are BASF SE (Germany), Ashland Global Holdings Inc. (US), Dowdupont Inc. (US), Roquette Freres (France), DFE Pharma (Germany), JRS Pharma (Germany), Asahi Kasei Corporation (Japan), Merck KGAA (Germany), and Corel Pharma Chem (India).
